SAGARD HEALTHCARE ROYALTY PARTNERS
Sagard Healthcare Royalty Partners is the royalty investment unit of private-equity firm of Sagard Holdings.
SAGARD HEALTHCARE ROYALTY PARTNERS
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-02 | Valeo Pharma | Sagard Healthcare Royalty Partners investment in Post-IPO Debt - Valeo Pharma | 40 M USD |
More informations about "Sagard Healthcare Royalty Partners"
Sagard Healthcare Partners - Sagard
Sagard Healthcare Partners invests in royalties and credit backed by approved and commercialized biopharmaceutical products, diagnostics and medical devices. We aim to …See details»
Sagard Healthcare Announces Closing of Credit Facility …
TORONTO, January 4, 2024 – Sagard Healthcare – a biopharmaceutical royalty and creditinvestor – today announced several developments and milestones for the strategy, including theclosing of a $250 million permanent credit facility …See details»
Sagard Healthcare Royalty Partners Closes $725 Million First Fund
Feb 18, 2021 Sagard develops long-term partnerships and empowers the growth of its investments through a unique global network of portfolio companies, limited partners, advisors …See details»
Sagard Holdings announces first closing of Sagard Healthcare …
Jan 9, 2020 Sagard develops long-term partnerships and empowers the growth of its investments through a unique global network of portfolio companies, limited partners, advisors …See details»
Home | HealthCare Royalty Partners
HealthCare Royalty Partners is an investment firm that purchases royalties and uses debt-like structures to invest in commercial stage assets.See details»
Sagard closes $725 million for biopharmaceutical royalty …
Feb 18, 2021 Sagard Holdings, the alternative asset manager arm of Power Corporation, has announced the final close of Sagard Healthcare Royalty Partners, LP (SHRP), pulling in $725 …See details»
Purchase and Sale Agreement by and between the Company and …
Jun 9, 2025 Purchase and Sale Agreement by and between the Company and Sagard Healthcare Partners, dated June 9, 2025 from MACROGENICS INC filed with the Securities …See details»
MacroGenics Secures $70M ZYNYZ Royalty Deal, Extends Cash …
2 days ago Demonstrating this new financial discipline, MacroGenics recently secured a significant non-dilutive capital infusion through a royalty purchase agreement. The company …See details»
Philippe Savard - Senior Principal, Sagard Healthcare …
Senior Principal, Sagard Healthcare Partners · Experience: Sagard · Location: Toronto · 500+ connections on LinkedIn. View Philippe Savard’s profile on LinkedIn, a professional community of 1 billion members.See details»
mgnx-20250630 - SEC.gov
Jun 30, 2025 Net cash provided by financing activities for the six months ended June 30, 2025 includes net cash proceeds of $69.7 million from Sagard Healthcare Partners (Sagard) under …See details»
History - Sagard
Launch of Sagard Healthcare Partners, an investment strategy that invests in credit backed by approved and commercialized biopharmaceutical products, diagnostics and medical devices, …See details»
Sagard Healthcare Announces Closing of Credit Facility and Recent ...
Jan 4, 2024 Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, includingSee details»
News Archives - Sagard
Press Releases Performance Equity Management Announces Reinvestment in EoS Fitness Jul 21, 2025See details»
Sagard Healthcare Royalty Partners - Financial Details
Sagard Healthcare Royalty Partners is the royalty investment unit of private-equity firm of Sagard Holdings.See details»
Sagard Healthcare Royalty Partners - Crunchbase
Sagard Healthcare Royalty Partners focuses on post-IPO debt investments in biotechnology, pharmaceutical, and biopharma industries, with a geographical focus in North America, …See details»
Sagard Healthcare
The Sagard Healthcare partners have been investing in this sector for more than two decades on average. They use their extensive experience to manage the Sagard Healthcare strategy, …See details»
Our board of directors | MGH Foundation
Sean McKinnon is the Head of Business Development at Sagard, a global multi-strategy alternative asset management firm. Prior to joining Sagard, Sean founded Mount Bruno …See details»
MacroGenics Extends Cash Runway to 2027 with $70M Royalty …
1 day ago The $70 million upfront payment from Sagard Healthcare Partners through the ZYNYZ royalty purchase agreement significantly bolsters their cash reserves, bringing their total to …See details»
Sagard closes $725 million for biopharmaceutical royalty …
Feb 18, 2021 Sagard Holdings, the alternative asset manager arm of Power Corporation, has announced the final close of Sagard Healthcare Royalty Partners, LP (SHRP), pulling in $725 …See details»
Raja Manchanda - Sagard
Prior to Sagard, Raja was a Vice President at DRI Capital, focused on sourcing royalty monetization investment opportunities from the academic and corporate sectors. Raja has …See details»